RESUMEN
Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty-one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension.
Asunto(s)
Bloqueadores de los Canales de Calcio/administración & dosificación , Bloqueadores de los Canales de Calcio/efectos adversos , Isradipino/administración & dosificación , Isradipino/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Adulto , Anciano , Bloqueadores de los Canales de Calcio/uso terapéutico , Humanos , Isradipino/uso terapéutico , Persona de Mediana Edad , Proyectos Piloto , Resultado del TratamientoRESUMEN
BACKGROUND: A wide variety of movement disorders may occur as a consequence of the administration of antiepileptic drugs (AEDs). Although it has been suggested that the risk of parkinsonism is 10-fold higher in those taking valproate as compared with other AEDs, there have been no large, systematic trials assessing this. AIM: To establish more precisely the prevalence of and risk factors for developing parkinsonism associated with valproate use,and to assess the occurrence of movement disorders with the newer AEDs. METHODS: Patients with epilepsy were recruited from the Toronto Western Hospital Epilepsy Clinic (University of Toronto, Toronto, Ontario, Canada). Each patient was examined by a movement disorder specialist who was blinded to the treatment status of the patient. RESULTS: 201 patients were included. Postural tremor was the most common movement disorder (45%), followed by parkinsonism (4.5%). The odds of having parkinsonism were 5 times higher with valproate than with other AEDs. No single factor predicted the presence of parkinsonism; however, many (5/9) of the patients concurrently used other drugs or had comorbidities that could have caused or exacerbated parkinsonism. None of the newer AEDs were clearly associated with the presence of movement disorders; however, the numbers were too small to make a formal analysis. CONCLUSION: Although the risk of parkinsonism with valproate is higher than with other AEDs, it is lower than originally reported. The cases available were not enough to accurately comment on the prevalence of movement disorders with the newer AEDs.
Asunto(s)
Anticonvulsivantes/efectos adversos , Trastornos Parkinsonianos/inducido químicamente , Ácido Valproico/efectos adversos , Adulto , Anciano , Anticonvulsivantes/uso terapéutico , Estudios Transversales , Epilepsia/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Ácido Valproico/uso terapéuticoRESUMEN
Essential palatal tremor (EPT) is an uncommon disorder, distinct from symptomatic palatal tremor (SPT), but characterized by superficially similar rhythmic movements of the soft palate. While the pathophysiology of SPT has been relatively well defined, this is not the case in EPT. Based on an analysis of 103 published cases, we reviewed EPT in the context of other movement disorders with similar features and outline possible pathophysiological mechanisms. Phenomenologically it remains best classified as a tremor. Four major causes, including a central generator, peripheral/mechanical, voluntary/special skill and psychogenic, appear to account for the majority of cases of EPT, although there is considerable overlap in the pathogenic mechanisms underlying these categories. Among the cases reviewed, a large proportion fit into the latter two categories, although there are others where multiple mechanisms are likely at play. Based on our reappraisal, we suggest a change in designation to 'isolated palatal tremor', with primary and secondary subtypes. This retains the distinction from SPT and emphasizes the non-uniform, heterogeneous nature of the disorder.
Asunto(s)
Temblor Esencial/clasificación , Enfermedades de la Boca/clasificación , Adolescente , Adulto , Niño , Temblor Esencial/etiología , Temblor Esencial/fisiopatología , Temblor Esencial/psicología , Humanos , Masculino , Enfermedades de la Boca/etiología , Enfermedades de la Boca/fisiopatología , Enfermedades de la Boca/psicología , Músculos Palatinos/fisiopatología , Paladar Blando/fisiopatología , Trastornos Psicofisiológicos/etiología , Terminología como AsuntoRESUMEN
BACKGROUND/AIMS: The role of cognitive reserve in Parkinson's disease (PD)-mild cognitive impairment (MCI) is incompletely understood. METHODS: The relationships between PD-MCI, years of education, and estimated premorbid IQ were examined in 119 consecutive non-demented PD patients using logistic regression models. RESULTS: Higher education and IQ were associated with reduced odds of PD-MCI in univariate analysis. In multivariable analysis, a higher IQ was associated with a significantly decreased odds of PD-MCI, but education was not. CONCLUSION: The association of higher IQ and decreased odds of PD-MCI supports a role for cognitive reserve in PD, but further studies are needed to clarify the interaction of IQ and education and the impact of other contributors such as employment and hobbies.
Asunto(s)
Muñones de Amputación , Trastornos del Movimiento/psicología , Adulto , Ansiedad , Atención , Depresión , Humanos , Masculino , Dolor/psicología , Estrés PsicológicoRESUMEN
Elevated homocysteine is associated with increased risk of heart disease, stroke, and dementia. Therapy of Parkinson disease (PD) with levodopa elevates homocysteine. The authors conducted a 6-week, multicenter, randomized, double-blind, placebo-controlled trial to test whether folate 1 mg/vitamin B(12) 500 microg or entacapone reduced serum homocysteine in 35 levodopa-treated PD patients. Levodopa initiation caused a small elevation in homocysteine. Vitamin therapy, but not entacapone, resulted in a decrease in homocysteine compared to placebo.
Asunto(s)
Catecoles/uso terapéutico , Ácido Fólico/administración & dosificación , Hiperhomocisteinemia/inducido químicamente , Hiperhomocisteinemia/prevención & control , Levodopa/efectos adversos , Vitamina B 12/administración & dosificación , Anciano , Antiparkinsonianos/uso terapéutico , Canadá , Método Doble Ciego , Combinación de Medicamentos , Femenino , Homocisteína/sangre , Humanos , Hiperhomocisteinemia/sangre , Levodopa/uso terapéutico , Masculino , Persona de Mediana Edad , Nitrilos , Enfermedad de Parkinson/sangre , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/tratamiento farmacológico , Efecto Placebo , Resultado del Tratamiento , Estados Unidos , Vitaminas/uso terapéuticoRESUMEN
A child with Down's syndrome, hydrocephalus and porencephaly is described, and treatment by compressive head binding is discussed. Although binding did not stop enlargement of the head it did achieve a reduction in the rate of enlargement.